Tibsovo Tablets 250mg

Get a Price/Quote

Tibsovo Tablets 250mg Specification

Brand Name
Tibsovo

Packaging Type
Bottle

Life Span
Check expiry date on bottle

Salt Composition
Ivosidenib 250mg

Origin of Medicine
USA

Dosage Form
Tablet

Indication
Treatment of acute myeloid leukemia (AML) with IDH1 mutation

Pacakaging (Quantity Per Box)
60 tablets per bottle

Drug Type
Prescription only

Ingredients
Ivosidenib

Physical Form
Tablet

Function
Anticancer (targeted therapy for leukemia)

Recommended For
Adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation

Dosage
250mg

Dosage Guidelines
As prescribed by the physician

Suitable For
Adults

Quantity
60 Tablets

Storage Instructions
Store below 30C and protect from moisture

Strength
250 mg per tablet

Color
White

Shape
Oval

Marketed By
Servier Pharmaceuticals

Country of Approval
Approved in USA, Canada, Australia, UK, EU

Route of Administration
Oral

Tibsovo Tablets 250mg About

Choose Tibsovo Tablets 250mg-an immaculate solution for adults battling relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation. Marketed by Servier Pharmaceuticals, this cost-effective targeted therapy harnesses the ravishing power of Ivosidenib, a redoubtable anticancer agent approved in the USA, Canada, Australia, the UK, and the EU. Each pristine white, oval tablet is designed for oral administration and delivers 250mg of potent medication. Conveniently packaged with 60 tablets per bottle, Pick Yours today and order under prescription for superior AML treatment outcomes.

Outstanding Features and Versatile Applications

Tibsovo Tablets 250mg are engineered with impeccable precision, harnessing machine-controlled excellence in their formulation and production. Intended for the specific treatment of relapsed or refractory AML with IDH1 mutations, these tablets are tailored for adult patients under a physician's guidance. While directly targeting leukemia, Tibsovo's design upholds general oral medication standards, ensuring seamless integration into hospitals and clinics. Its rigorous manufacturing process and adaptive dosage suit diverse oncology healthcare environments.

Detailed Packaging and Optimized Delivery Solutions

Tibsovo Tablets are expertly packaged in robust bottles containing 60 tablets, ensuring protection against moisture and damage during transportation. Our logistics prioritize safe, swift Express Shipping to hospitals and pharmacies across various regions, adapting to specific handling requirements. Delivery timeframes are streamlined for prompt access, supporting patient needs efficiently. Sample policies are available for verified healthcare providers to facilitate clinical evaluation. Our comprehensive logistics network guarantees secure, reliable, and timely order fulfillment.

FAQ's of Tibsovo Tablets 250mg:

Q: How should Tibsovo Tablets 250mg be stored to maintain their efficacy?

A: Tibsovo Tablets must be stored below 30C and protected from moisture. Always check the expiry date on the bottle before use.

Q: What is the main usage of Tibsovo Tablets 250mg?

A: Tibsovo is prescribed for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a susceptible IDH1 mutation, acting as a targeted anticancer therapy.

Q: When is it appropriate to start Tibsovo treatment?

A: Tibsovo should be started only upon prescription from an oncologist after confirming the presence of an IDH1 mutation in relapsed or refractory AML cases.

Q: Where is Tibsovo Tablets 250mg approved and available?

A: Tibsovo is approved for therapeutic use in the USA, Canada, Australia, the UK, and the European Union, and it is available upon prescription in these regions.

Q: What is the process for ordering Tibsovo Tablets in India?

A: Order Tibsovo Tablets through authorized suppliers, traders, or pharmaceutical distributors in India. Prescription from a qualified healthcare professional is mandatory.

Q: How does Tibsovo benefit patients with AML?

A: Tibsovo targets and inhibits mutant IDH1 enzymes in leukemia cells, providing a potent therapeutic option for patients unresponsive to conventional treatments.

Tell us about your requirement